Principia Biopharma (NASDAQ:PRNB) reported that PRN1371 was well tolerated in the dose escalation portion of its Phase 1 trial in adult patients with advanced solid tumors.
PRN1371, a fibroblast growth factor receptor (FGFR) inhibitor, also demonstrated stable disease in 11 of 36 patients after two 28-day treatment cycles.
“As with other FGFR inhibitors, in a non-selected patient population, we did not see partial or complete responses,” Martin Babler, Principia’s president and CEO, said in a statement.
“However, we are encouraged by the observed duration of stable disease, by the remaining two patients on study, and by the established tolerability profile of our molecule,” he added.
Principia is currently conducting the cohort expansion portion of the Phase 1 study in metastatic urothelial carcinoma patients with identified FGFR mutations.
